Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) just unveiled an announcement.
Fusen Pharmaceutical Co., Ltd. has announced significant changes in its board composition effective from September 30, 2025. Mr. Sze Wing Chun has resigned as an independent non-executive director and chairman of the Audit Committee, while Mr. Yu Ho Ming has been appointed as an independent non-executive director and a member of the Audit Committee. Additionally, Mr. Lee Kwok Tung Louis has been appointed as the chairman of the Audit Committee. These changes are expected to bring new expertise and perspectives to the company’s governance, potentially impacting its strategic direction and stakeholder relations.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company, along with its subsidiaries, focuses on the development and distribution of pharmaceutical products.
Average Trading Volume: 2,177,365
Technical Sentiment Signal: Buy
Current Market Cap: HK$514.7M
See more data about 1652 stock on TipRanks’ Stock Analysis page.